Biogen Inc. $BIIB Stock Holdings Lifted by Gateway Investment Advisers LLC

Key Points

• Gateway Investment Advisers LLC raised its Biogen stake by 13.8% to 48,161 shares (about $8.48M), and institutional investors now own roughly 87.93% of the stock.
• Analyst views are mixed: Wolfe Research and Needham raised longer‑term EPS outlooks but sharply cut Q2‑2026 estimates, Canaccord reaffirmed a Buy, and the consensus is a Moderate Buy with an average target of $214.23.
• Biogen beat Q1 expectations with $3.57 EPS and $2.48B revenue, issued FY2026 guidance of $14.25–$15.25 EPS, and currently trades near $191 with a $28.25B market cap and a P/E of 20.53.

Gateway Investment Advisers LLC lifted its position in Biogen Inc. (NASDAQ:BIIB - Free Report) by 13.8% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 48,161 shares of the biotechnology company's stock after acquiring an additional 5,835 shares during the period. Gateway Investment Advisers LLC's holdings in Biogen were worth $8,476,000 as of its most recent SEC filing.

Several other institutional investors have also made changes to their positions in BIIB. WPG Advisers LLC grew its position in Biogen by 417.9% during the fourth quarter. WPG Advisers LLC now owns 145 shares of the biotechnology company's stock valued at $26,000 after purchasing an additional 117 shares in the last quarter. Accredited Wealth Management LLC grew its position in Biogen by 1,233.3% during the third quarter. Accredited Wealth Management LLC now owns 200 shares of the biotechnology company's stock valued at $28,000 after purchasing an additional 185 shares in the last quarter. First Horizon Corp purchased a new position in Biogen during the fourth quarter valued at approximately $30,000. WFA of San Diego LLC purchased a new position in Biogen during the second quarter valued at approximately $32,000. Finally, GoalVest Advisory LLC purchased a new position in Biogen during the fourth quarter valued at approximately $35,000. 87.93% of the stock is owned by hedge funds and other institutional investors.

Key Biogen News

Here are the key news stories impacting Biogen this week:

• Positive Sentiment: Wolfe Research and Needham published multi‑year upside: Wolfe projects FY2027–FY2030 EPS rising to $17.59, $18.94 and $21.17 (FY30), signaling stronger long‑term growth expectations; Needham’s longer‑range numbers (FY2027–FY2030) are also above current consensus in some years. These upward longer‑term views support a constructive medium/long‑term thesis.
• Positive Sentiment: Canaccord Genuity reaffirmed a Buy on BIIB, providing some buy‑side support for the shares. Canaccord Genuity Sticks to Its Buy Rating for Biogen (BIIB)
• Neutral Sentiment: Barclays and BMO Capital both maintained Hold ratings on BIIB — this keeps a portion of the broker community neutral rather than adding downward pressure. Barclays Keeps Their Hold Rating on Biogen (BIIB) BMO Capital Reaffirms Their Hold Rating on Biogen (BIIB)
• Neutral Sentiment: An unrelated press item on Giant Biogene (HK:2367) appeared in feeds; it does not pertain to Biogen (BIIB) but may have cluttered news flow. Giant Biogene Sets 2026 AGM
• Negative Sentiment: Wolfe Research cut its Q2 2026 EPS estimate sharply (from $3.78 to $3.11), a near‑term downgrade that could pressure sentiment around upcoming quarterly performance.
• Negative Sentiment: Needham also slashed its Q2 2026 EPS estimate (from $4.40 to $2.90), another notable near‑term revision that increases uncertainty for the next reported quarter.

Biogen Stock Performance

BIIB stock opened at $191.38 on Friday. The company has a quick ratio of 2.41, a current ratio of 3.06 and a debt-to-equity ratio of 0.34. The company has a market capitalization of $28.25 billion, a price-to-earnings ratio of 20.53, a P/E/G ratio of 1.67 and a beta of 0.19. Biogen Inc. has a 12 month low of $115.25 and a 12 month high of $202.41. The firm has a 50 day moving average of $184.27 and a two-hundred day moving average of $177.50.

Biogen (NASDAQ:BIIB - Get Free Report) last posted its earnings results on Wednesday, April 29th. The biotechnology company reported $3.57 EPS for the quarter, topping the consensus estimate of $2.95 by $0.62. The company had revenue of $2.48 billion during the quarter, compared to the consensus estimate of $2.29 billion. Biogen had a net margin of 13.81% and a return on equity of 12.83%. The company's revenue for the quarter was up 1.9% compared to the same quarter last year. During the same period in the previous year, the firm posted $3.02 earnings per share. Biogen has set its FY 2026 guidance at 14.250-15.250 EPS. As a group, equities analysts anticipate that Biogen Inc. will post 14.31 EPS for the current fiscal year.

Insider Buying and Selling

In other news, insider Priya Singhal sold 2,660 shares of the business's stock in a transaction on Monday, February 9th. The shares were sold at an average price of $199.83, for a total value of $531,547.80. Following the completion of the sale, the insider directly owned 8,043 shares in the company, valued at approximately $1,607,232.69. The trade was a 24.85% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 0.18% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

A number of research analysts recently commented on BIIB shares. Tudor Pickering set a $201.00 price objective on shares of Biogen in a research report on Monday, February 9th. Weiss Ratings raised shares of Biogen from a "hold (c-)" rating to a "hold (c)" rating in a research report on Friday, May 1st. The Goldman Sachs Group boosted their price objective on shares of Biogen from $231.00 to $238.00 and gave the company a "buy" rating in a research report on Friday, April 24th. UBS Group raised shares of Biogen from a "neutral" rating to a "buy" rating and boosted their price objective for the company from $185.00 to $225.00 in a research report on Wednesday, April 22nd. Finally, Freedom Capital raised shares of Biogen from a "hold" rating to a "strong-buy" rating in a research report on Friday, May 1st. One investment analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating, thirteen have given a Hold rating and one has given a Sell rating to the company's stock. According to MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average target price of $214.23.

Biogen Profile

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer's disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company's marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.